Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
Epilepsy Res. 2009 Dec;87(2-3):120-3. doi: 10.1016/j.eplepsyres.2009.08.001. Epub 2009 Sep 5.
Pregabalin (PGB) is a new antiepileptic drug (AED) which is a structural, non-functional analogue of gamma-aminobutyric acid. It acts at presynaptic calcium channels to modulate neurotransmitter release in the CNS. While the efficacy and tolerability of PGB have been demonstrated in several randomised controlled trials, few studies have addressed long-term outcome in large groups of patients. A cohort of patients attending a tertiary referral centre for epilepsy was identified as having started taking PGB. Patients' data were obtained through medical records. Of 402 patients included, 42% of patients were still taking PGB at last follow-up. The estimated 2.5-year retention rate was 32%. Males appeared more likely to continue on PGB therapy than females. The common adverse experiences (AEs) leading to withdrawal were CNS-related, psychiatric AEs and weight gain. Published retention rates for levetiracetam appear to be higher, and those for gabapentin lower, than the rates estimated for PGB.
普瑞巴林（PGB）是一种新型抗癫痫药物（AED），是γ-氨基丁酸的结构非功能性类似物。它在突触前钙通道起作用，调节中枢神经系统中神经递质的释放。虽然普瑞巴林的疗效和耐受性已在几项随机对照试验中得到证实，但很少有研究在大量患者中探讨长期结果。确定了一个在癫痫三级转诊中心就诊的患者队列，他们开始服用普瑞巴林。通过病历获得患者的数据。在纳入的 402 名患者中，42%的患者在最后一次随访时仍在服用普瑞巴林。估计 2.5 年的保留率为 32%。男性比女性更有可能继续接受普瑞巴林治疗。导致停药的常见不良反应（AE）与中枢神经系统相关、精神科 AE 和体重增加有关。已发表的左乙拉西坦保留率似乎高于普瑞巴林，而加巴喷丁的保留率则低于普瑞巴林。
